Sun Pharma Arm Gets Relief From U.S. Court In Patent Infringement Case
A lawsuit alleged trade secret misappropriation, patent infringement of DUSA’s photodynamic therapy patents covering its product.
Sun Pharmaceutical Industries Ltd. on Wednesday said its arm DUSA Pharmaceuticals has received relief from a U.S. court in a patent infringement case.
Massachusetts-based DUSA has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG from using its confidential and proprietary trade secret information, Sun Pharmaceutical Industries said in a regulatory filing.
Earlier this year, DUSA, which is wholly-owned by Sun Pharma, filed a lawsuit against the Biofrontera defendants in the U.S. District Court for the District of Massachusetts. The lawsuit alleged trade secret misappropriation and patent infringement of DUSA’s photodynamic therapy patents covering its product.
DUSA, in its amended complaint filed in July, additionally alleged the Biofrontera defendants misappropriated confidential and trade secret information by obtaining confidential information from its former employees to sell and market defendants' own products.
The lawsuit sought an assessment of both damages and injunctive relief against the Biofrontera defendants, Sun Pharma said.
The court's order prohibits Biofrontera from making use of or disseminating DUSA's sales and financial information, customer lists and customer target lists, training and marketing materials, standard operating procedures, technical information, and unpublished clinical data, and any derivations thereof, effective immediately, it added.
Sun Pharma shares ended 2.23 percent lower at Rs 414 apiece on the BSE.